EMVision Medical Devices Limited (ASX:EMV), the Australian medtech developing a world-first portable brain scanner for stroke, will be in attendance at this year’s RSNA Annual Conference, to showcase its bedside (production equivalent) and first responder (concept) portable brain scanners for the first time in the US.

The company is currently running multi-centre clinical trials at leading comprehensive stroke centres in Australia, to support the path to market for its scanners to aid in the rapid assessment of suspected ischemic or haemorrhagic stroke at the point-of-care.

emu™ – bedside device

EMVision’s bedside device is a portable, cost-effective, non-ionising and safe brain scanner, capable of completing a neurological exam in under ten minutes.

The device can be easily wheeled around and has a headset mounted on an articulated arm that is placed on the patient’s head and pairs non-ionising ultra high frequency radio signals with powerful artificial intelligence, to produce rapid images of the brain to aid in the assessment of suspected stroke.

Targeted for use in ICUs, stroke wards and remote communities, the bedside device is undergoing multi-site clinical trials at major comprehensive stroke centres across Australia, including Liverpool Hospital, Royal Melbourne Hospital and Princess Alexandra Hospital, currently enrolling 150 suspected stroke patients.

First responder device

EMVision has also recently announced that an advanced 28-antenna prototype of its second-generation ‘first responder’ ultra-lightweight helmet scanner, designed for road and air ambulance deployment, has been assembled for bench testing.

The Gen II headset weighs under 22lbs and is intended to be transported to the point-of-care via a backpack. It contains a 28-antenna 3D array designed to provide entire brain coverage in a single scan, with high-performance ultra-light weight antennas. A silicone membrane with coupling media provides coupling of the antennas to the head. This membrane has been designed as a reusable but replaceable component and the coupling media will be a per-scan consumable item.

This advanced prototype is a precursor to the ‘proof of concept’ system, suitable for pre-hospital deployment, which is on track to be assembled in the first half of calendar year 2024. It will then be used for planned road/air ambulance trials under EMVision’s collaboration with the Australian Stroke Alliance.